To examine the drug-specific interactions between pyrotinib and apatinib in HER2-positive GC, we assessed the tumor-suppressive efficacy of the inhibitors alone or combined in NCI-N87 xenografts (Fig. 2k–n). The gene discussed is ERBB2; the disease is gastric cancer.